Claims Cover the Use of Ibudilast for Primary or Secondary Progressive Multiple Sclerosis
February 1, 2012
SAN DIEGO, Calif., Feb. 1, 2012 (GLOBE NEWSWIRE) — MediciNova Inc, a biopharmaceutical company traded on the NASDAQ Global Market and the Jasdaq Market of the Osaka Securities Exchange, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers the use of ibudilast for the treatment of progressive forms of multiple sclerosis. Ibudilast (MN-166), is the company’s lead drug development candidate for certain neurological conditions, including progressive multiple sclerosis, neuropathic pain, and drug addiction.
A patent maturing from this allowed patent application is expected to expire no earlier than early 2029 and covers a method of treating primary progressive multiple sclerosis (PPMS) or secondary progressive MS (SPMS) by administering ibudilast either alone or in combination with other drugs. The patent application is based upon clinical investigations conducted by MediciNova researchers which showed an apparent disease-modifying benefit in which brain volume loss, or brain atrophy, commonly associated with disease progression, was reduced by oral administration of ibudilast to a group of multiple sclerosis patients including some subjects with progressive multiple sclerosis, in a dose-related fashion over at least a 10-month treatment period.
..
..Comments for each blog posting are always appreciated.
Please use the link found below, to leave comments.. .. All comments are moderated to reduce SPAM and bad language
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
– Click to: REGISTER – For our MS weekly e-Newsletter
“Providing You with ‘MS Views and News’, IS What We Do”
Help us to educate $ DONATE NOW PLEASE $
“MS Views and News” is a 501©(3) Not-For-Profit organization
as recognized by the Internal Revenue Service
All contributions are tax deductible to the fullest extent allowed by law
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Disclaimer: ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
…………………………
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
